QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.83 (+1.39%)
F   12.00 (+0.42%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.42 (+1.62%)
AMC   4.81 (+8.09%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.83 (+1.39%)
F   12.00 (+0.42%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.42 (+1.62%)
AMC   4.81 (+8.09%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.83 (+1.39%)
F   12.00 (+0.42%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.42 (+1.62%)
AMC   4.81 (+8.09%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.83 (+1.39%)
F   12.00 (+0.42%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.42 (+1.62%)
AMC   4.81 (+8.09%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
NASDAQ:TBIO

Telesis Bio (TBIO) Stock Price, News & Analysis

$0.58
-0.08 (-12.17%)
(As of 02/27/2024 ET)
Today's Range
$0.50
$0.61
50-Day Range
$0.31
$0.78
52-Week Range
$0.30
$3.32
Volume
730,188 shs
Average Volume
1.14 million shs
Market Capitalization
$17.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Telesis Bio MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.05mentions of Telesis Bio in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.16) to ($0.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.83 out of 5 stars

Medical Sector

637th out of 945 stocks

Analytical Instruments Industry

20th out of 28 stocks


TBIO stock logo

About Telesis Bio Stock (NASDAQ:TBIO)

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system, including BioXp 3250 system, BioXp 9600 system, and BioXp DBC, which are empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits, such as BioXp De Novo kits, BioXp select kits, BioXp next generation sequencing kits, and BioXp DBC kits, which contains building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and short oligo ligation assembly enzymatic DNA synthesis designs to significantly reduce timelines for constructing synthetic DNA, RNA, and proteins compared to traditional chemical synthesis, paving the way for more efficient and effective development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

TBIO Stock Price History

TBIO Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Why Is Telesis Bio (TBIO) Stock Up 29% Today?
Telesis Bio, Inc. (TBIO)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Telesis Bio Appoints William Kullback CFO
Telesis Bio appoints William Kullback as CFO
Telesis Bio Appoints William J. Kullback Chief Financial Officer
Telesis Bio (TBIO) Receives a Rating Update from a Top Analyst
Telesis Bio: Q2 Earnings Snapshot
Telesis Bio (NASDAQ: DNAY)
Telesis Bio Inc (TBIO)
See More Headlines
Receive TBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
2/27/2024
Next Earnings (Estimated)
3/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:TBIO
Previous Symbol
NASDAQ:DNAY
Fax
N/A
Employees
223
Year Founded
N/A

Profitability

Net Income
$-48,470,000.00
Net Margins
-127.49%
Pretax Margin
-127.14%

Debt

Sales & Book Value

Annual Sales
$30.00 million
Book Value
$1.58 per share

Miscellaneous

Free Float
20,689,000
Market Cap
$15.59 million
Optionable
Optionable
Beta
1.61
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Todd R. Nelson MBA (Age 57)
    Ph.D., CEO & Director
    Comp: $924.38k
  • Mr. Daniel G. Gibson Ph.D. (Age 47)
    Chief Technology Officer
    Comp: $590.37k
  • Mr. Robert H. Cutler (Age 56)
    Chief Legal Officer
    Comp: $568.58k
  • Mr. Eric Esser (Age 56)
    President & COO
  • Mr. William J. Kullback (Age 64)
    Chief Financial Officer
  • Ms. Jen Carroll
    Vice President of Investor Relations
  • Ms. Laura B. Puga M.B.A. (Age 44)
    Vice President of People & Culture
  • Mr. Decky Goodrich M.B.A.
    Senior Vice President of Commercial Operations
  • Mr. Laurence Warden
    Senior Vice President of Engineering & Instrumentation
  • Richard Lepke
    Director of Investor Relations














TBIO Stock Analysis - Frequently Asked Questions

How have TBIO shares performed in 2024?

Telesis Bio's stock was trading at $0.3990 at the beginning of the year. Since then, TBIO stock has increased by 44.7% and is now trading at $0.5773.
View the best growth stocks for 2024 here
.

When is Telesis Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024.
View our TBIO earnings forecast
.

How were Telesis Bio's earnings last quarter?

Telesis Bio, Inc. (NASDAQ:TBIO) released its quarterly earnings data on Monday, November, 8th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.06. The firm earned $2.79 million during the quarter, compared to analysts' expectations of $2.93 million. Telesis Bio had a negative net margin of 127.49% and a negative trailing twelve-month return on equity of 118.72%.

What guidance has Telesis Bio issued on next quarter's earnings?

Telesis Bio updated its fourth quarter 2023 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.0 million-$7.0 million, compared to the consensus revenue estimate of $9.5 million.

What is Craig J. Tuttle's approval rating as Telesis Bio's CEO?

13 employees have rated Telesis Bio Chief Executive Officer Craig J. Tuttle on Glassdoor.com. Craig J. Tuttle has an approval rating of 5% among the company's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Telesis Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Telesis Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA), Johnson & Johnson (JNJ), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and VBI Vaccines (vbiv).

When did Telesis Bio IPO?

(TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO.

Who are Telesis Bio's major shareholders?

Telesis Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Bridgeway Capital Management LLC (0.22%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Telesis Bio?

Shares of TBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TBIO) was last updated on 2/27/2024 by MarketBeat.com Staff